Clinical Trial Update: Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis [Phase 2]

View source ↗

Summary

Novartis completed a Phase II efficacy study of a single-dose regimen of AIN457 for chronic plaque psoriasis. Results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• AIN457

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2015-02-18